Celldex's barzolvolimab meets Phase 3 endpoints in chronic hives trial

September 22, 2026 6:58 AM

Celldex Therapeutics (NASDAQ: CLDX) reported positive topline results from two Phase 3 trials of barzolvolimab in patients with chronic spontaneous ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found